CD38 and adenocarcinoma: Deletion of the Cd38 gene reduced tumor formation in both Arh1-deficient and wild-type mice [49], with significant reductions in the incidence of lymphomas, adenocarcinoma, and hemangio/histolytic sarcomas [49].